Insider · CIK 0001192128

BESHAR LUKE M

Reports to the SEC for 6 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001192128

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-15	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+31K sh	—	—	31,000
2025-06-12	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+24K sh	—	—	24,000
2024-06-07	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2023-06-07	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2023-06-07	Omega Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+18.1K sh	—	—	18,118
2022-06-30	TARAProtara Therapeutics, Inc.P Purchase	Director	PPurchase	+10K sh	$3.10	+$31K	198,000
2022-06-08	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2022-06-08	Omega Therapeutics, Inc.Option (Right to Buy)A Award	Director	AAward	+18.1K sh	—	—	18,118
2022-03-14	TARAProtara Therapeutics, Inc.P Purchase	Director	PPurchase	+10K sh	$4.25	+$42.5K	188,000
2022-03-10	TARAProtara Therapeutics, Inc.P Purchase	Director	PPurchase	+10K sh	$4.46	+$44.6K	178,000
2021-11-17	Trillium Therapeutics Inc.Deferred Share UnitD Disposition to Issuer	Director	DDisposition to Issuer	−548K sh	—	—	0
2021-11-17	Trillium Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−40K sh	—	—	0
2021-11-17	Trillium Therapeutics Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,666 sh	—	—	0
2021-07-29	Omega Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+52.9K sh	—	—	52,941
2021-06-09	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2021-06-04	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2020-06-09	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2020-05-29	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2020-01-10	TARAProtara Therapeutics, Inc.A Award	Director	AAward	+168K sh	—	—	168,000
2020-01-09	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,676 sh	—	—	6,676
2020-01-09	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.4K sh	—	—	12,399
2020-01-09	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,676 sh	—	—	6,676
2020-01-09	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10.5K sh	—	—	10,491
2020-01-09	TARAProtara Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.4K sh	—	—	12,399
2019-05-31	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2018-11-29	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−12.8K sh	—	—	53,000
2018-11-29	RGNXREGENXBIO Inc.S Sale	Director	SSale	−12.8K sh	$65.00	−$831K	0
2018-11-29	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+12.8K sh	$3.76	+$48.1K	12,784
2018-11-27	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,687 sh	$22.00	+$103K	5,570
2018-11-27	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+883 sh	$49.45	+$43.7K	883
2018-11-27	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−716 sh	—	—	65,784
2018-11-27	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−6,250 sh	—	—	0
2018-11-27	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,687 sh	—	—	0
2018-11-27	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−883 sh	—	—	7,292
2018-11-27	RGNXREGENXBIO Inc.S Sale	Director	SSale	−18.8K sh	$65.03	−$1.22M	0
2018-11-27	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+716 sh	$3.76	+$2,692.16	18,786
2018-11-27	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+6,250 sh	$12.74	+$79.6K	18,070
2018-11-27	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−6,250 sh	—	—	0
2018-11-27	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+6,250 sh	$18.85	+$118K	11,820
2018-11-26	RGNXREGENXBIO Inc.S Sale	Director	SSale	−1,721 sh	$65.00	−$112K	0
2018-11-26	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,721 sh	$49.45	+$85.1K	1,721
2018-11-26	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,721 sh	—	—	8,175
2018-11-20	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+13.5K sh	$3.76	+$50.8K	21,176
2018-11-20	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,988 sh	$12.74	+$38.1K	7,676
2018-11-20	RGNXREGENXBIO Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,688 sh	$22.00	+$103K	4,688
2018-11-20	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,688 sh	—	—	4,687
2018-11-20	RGNXREGENXBIO Inc.S Sale	Director	SSale	−21.2K sh	$60.38	−$1.28M	0
2018-11-20	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,988 sh	—	—	6,250
2018-11-20	RGNXREGENXBIO Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−13.5K sh	—	—	66,500
2018-11-19	RGNXREGENXBIO Inc.S Sale	Director	SSale	−600 sh	$63.53	−$38.1K	0

Recent filings

Accepted (ET)
Jun 164
BESHAR LUKE M0001213900-26-069243
SEC(opens sec.gov)
Jun 134
BESHAR LUKE M0001213900-25-054280
SEC(opens sec.gov)
Jun 104
BESHAR LUKE M0001213900-24-051375
SEC(opens sec.gov)
Jun 94
BESHAR LUKE M0000899243-23-015150
SEC(opens sec.gov)
Jun 84
BESHAR LUKE M0001213900-23-047470
SEC(opens sec.gov)
Jul 54
BESHAR LUKE M0001213900-22-037266
SEC(opens sec.gov)
Jun 104
BESHAR LUKE M0000899243-22-021895
SEC(opens sec.gov)
Jun 94
BESHAR LUKE M0001213900-22-031989
SEC(opens sec.gov)
Mar 164
BESHAR LUKE M0001209191-22-019238
SEC(opens sec.gov)
Mar 144
BESHAR LUKE M0001209191-22-018478
SEC(opens sec.gov)
Nov 194
BESHAR LUKE M0001104659-21-141748
SEC(opens sec.gov)
Jul 304
BESHAR LUKE M0000899243-21-030838
SEC(opens sec.gov)
Jun 104
BESHAR LUKE M0001209191-21-039680
SEC(opens sec.gov)
Jun 84
BESHAR LUKE M0001562180-21-004125
SEC(opens sec.gov)
Jun 114
BESHAR LUKE M0001209191-20-035843
SEC(opens sec.gov)
Jun 114/A
BESHAR LUKE M0001209191-20-035842
SEC(opens sec.gov)
Jun 24
BESHAR LUKE M0001562180-20-004063
SEC(opens sec.gov)

Companies

Address

C/O PROTARA THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, 3RD FLOOR

NEW YORK, NY, 10010